Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

Macular DiseasesRetinal Diseases

Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis

Ophthalmol Retina

Lakhani M, Kwan ATH, Kundapur D, Popovic MM, Damji KF, Hurley BR

doi: 10.1016/j.oret.2025.08.018

Macular Diseases

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Acta Ophthalmol

Falemban AH, Söderberg-Löfdal K, Jonsson F, Almlöf-Sarman S, von Euler M, Westborg I

doi: 10.1111/aos.17534

Retinal Diseases

Treatment Patterns and Long-Term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database

Ophthalmol Retina

Ip M, Modi Y, Fekrat S, Gibson K, Boucher N, Arrisi P, Ishii F, Liu Y, Paris LP, Fenech M, Chi GC

doi: 10.1016/j.oret.2025.05.025

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Acta Ophthalmol

Butler ETS, Arnold-Vangsted A, Schou MG, Anguita R, Bjerager J, Borrelli E, Cehofski LJ, Ferro Desideri L, van Dijk EHC, Faber C, Grauslund J, Hajari JN, Huemer J, Klefter ON, Krogh Nielsen M, Sabaner MC, Schneider M, Subhi Y

doi: 10.1111/aos.17506

Macular Diseases

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

J Clin Med

Teper S, Ledwoń D, Romaniszyn-Kania P, Sendecki A, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M

doi: 10.3390/jcm14196771

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Retinal Diseases

Systemic Thromboembolic Outcomes in Young Patients Following Retinal Vein Occlusions

Retina

Zhang C, Ayoubi M, Lin JB, AbouKasm G, Sonik NR, Sosa-Lockwood J, Berrocal A

doi: 10.1097/IAE.0000000000004700

Macular Diseases

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Ophthalmol Ther

Shellvarajah M, Nguyen V, Steinmann S, Gillies MC, Sagkriotis A, Barthelmes D

doi: 10.1007/s40123-025-01140-z

Related content

Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Treatment Patterns and Long-Term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Systemic Thromboembolic Outcomes in Young Patients Following Retinal Vein Occlusions

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study